Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 760.00K | 1.04M | 4.01M | 4.74M | 1.08M | 71.00K |
Gross Profit | 7.00K | -1.75M | 4.01M | 3.35M | -184.00K | -56.93M |
EBITDA | -373.49M | -338.85M | -221.51M | -166.90M | -106.78M | -72.59M |
Net Income | -328.25M | -298.41M | -214.53M | -159.95M | -106.72M | -72.86M |
Balance Sheet | ||||||
Total Assets | 1.36B | 1.43B | 635.35M | 352.18M | 351.01M | 183.44M |
Cash, Cash Equivalents and Short-Term Investments | 1.27B | 1.35B | 558.55M | 334.43M | 333.71M | 170.88M |
Total Debt | 50.82M | 51.72M | 51.73M | 2.02M | 3.07M | 4.01M |
Total Liabilities | 107.33M | 109.79M | 96.25M | 35.85M | 19.07M | 14.53M |
Stockholders Equity | 1.25B | 1.32B | 539.11M | -439.17M | -275.25M | -167.61M |
Cash Flow | ||||||
Free Cash Flow | -265.32M | -229.81M | -171.00M | -116.86M | -89.02M | -62.21M |
Operating Cash Flow | -261.57M | -225.97M | -166.31M | -115.20M | -88.59M | -62.03M |
Investing Cash Flow | -661.09M | -574.82M | -200.41M | -173.98M | -56.48M | 217.00K |
Financing Cash Flow | 621.30M | 1.01B | 388.94M | 121.96M | 252.68M | 114.57M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
78 Outperform | $3.57B | 15.46 | 37.24% | ― | 22.42% | ― | |
63 Neutral | S$1.56B | 3.70 | 2.87% | 4.71% | 17.84% | 20.03% | |
53 Neutral | $3.00B | ― | -14.40% | ― | ― | -23.84% | |
53 Neutral | $2.25B | ― | -103.82% | ― | 48.04% | 48.16% | |
51 Neutral | $2.66B | ― | -30.84% | ― | ― | -1.20% | |
50 Neutral | $3.21B | ― | -106.71% | ― | ― | -22.34% | |
45 Neutral | $2.76B | ― | -62.46% | ― | ― | -43.10% |
On June 30, 2025, Crinetics Pharmaceuticals announced that it will present eight abstracts from its clinical development programs at the Endocrine Society’s Annual Meeting, ENDO 2025, in San Francisco. The presentations will include long-term efficacy and safety data on PALSONIFY for acromegaly, results from a Phase 2 trial of atumelnant for congenital adrenal hyperplasia, and early-stage data on CRN12755 for Graves’ hyperthyroidism. These developments highlight Crinetics’ commitment to addressing unmet needs in endocrine disorders and reinforce its position as a leader in endocrine-focused pharmaceutical innovation.
The most recent analyst rating on (CRNX) stock is a Buy with a $62.00 price target. To see the full list of analyst forecasts on Crinetics Pharmaceuticals stock, see the CRNX Stock Forecast page.
On June 26, 2025, Crinetics Pharmaceuticals held a Research and Development Day in New York, presenting updates on its preclinical pipeline. Key highlights included the development of CRN12755 for Graves’ disease, CRN10329 for polycystic kidney disease, and CRN09682 for neuroendocrine tumors. The event showcased promising preclinical data and outlined strategic plans for clinical trials, indicating potential advancements in treatment options for these conditions.
The most recent analyst rating on (CRNX) stock is a Buy with a $62.00 price target. To see the full list of analyst forecasts on Crinetics Pharmaceuticals stock, see the CRNX Stock Forecast page.
At the annual meeting of Crinetics Pharmaceuticals‘ stockholders held on June 11, 2025, key decisions were made, including the election of three Class I directors for three-year terms, the ratification of BDO USA, P.C. as the independent accounting firm, and the approval of executive compensation. These decisions reflect strong shareholder support and are likely to influence the company’s strategic direction and governance structure.
The most recent analyst rating on (CRNX) stock is a Buy with a $62.00 price target. To see the full list of analyst forecasts on Crinetics Pharmaceuticals stock, see the CRNX Stock Forecast page.